Last updated on August 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Psoriasis and Psoriatic Disorders
  • Gender: Male or Female

Key Inclusion Criteria:

  • Healthy male or female age >18 years
  • Have a diagnosis of moderate to severe plaque psoriasis (10% Body Surface Area involved)
  • Have had a diagnosis of chronic plaque psoriasis for at least 6 months
  • Have failed other forms of therapy for psoriasis, including topical steroids, phototherapy, or prior systemic therapy are a candidate for biologic therapy and have never been given an IL-17 inhibitor in the past
  • Are able to attend appointments for 52 weeks
  • Are willing to not use any other psoriasis treatment during the study

Key Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque psoriasis
  • Previous exposure to secukinumab or other injectable medications directly targeting IL-17A or IL-17RA receptors
  • Diagnosis of active skin infections (bacterial, fungal, viral) or other active ongoing skin diseases
  • Subjects using cholesterol-lowering medication (e.g., statins) and not on a stable dose for at least 90 days prior to randomization and unable to remain on a stable dose for the duration of the study
  • Women who are pregnant, planning to become pregnant, or of child-bearing potential and not willing to use effective contraception
  • Current severe progressive or uncontrolled disease including uncontrolled diabetes (hemoglobin Alc >7%), myocardial infarction within 6 months prior to screening, unstable heart disease, stroke, kidney disease, uncontrolled high blood pressure (systolic >180 mmHg, diastolic >95 mmHg), cancer within the past 5 years, active tuberculosis, certain significant abnormalities in blood work, and other major medical conditions.
  • History of HlV, Hepatitis C, or Hepatitis B
  • History or evidence of ongoing substance abuse within 12 months prior to screening, or not willing to limit alcohol use to ≤14 drinks per week within 4 weeks prior to Baseline and throughout the duration of the study
  • Allergy to rubber or latex

Other inclusion and exclusion criteria may apply.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.